Ann: SNT to present in MST Access Hidden Gems Webinar, page-41

This does seem a bit of fearmongering for the sake of it. Do you hope to drive or keep the price down? Genuine question.

One year's time is a long, long, way away, and you are NOT considering a single, promising result from any of the 4 trials, even though SNT have already demonstrated promise in both blood cancer AND scarring repair. Yes all trials are uncertain, but there are indicators there for success.

In the interim, the facts are that the company does have 4 x Ph2 trials scheduled to complete before mid-2025, they have declared that they are fully funded to their completion, that they do have $7m cash + another $7m coming + funding from Parkinsons UK & also the MRFF.

SNT own the IP outright, no licensing - so until a deal is made they are entitled to full ownership & any royalties going forward. 60% of the company is owned by Institutions and the recent $10m cap raise at 2.2c was fully subscribed, with more than one insto significantly increasing their holdings in SNT.

I don't think any reasonable person would expect the board to look any further forward for funding than the existing 12 months, whilst awaiting outcomes from 4 x Ph2 trials. Plus, the interim data for SNT's lead product, SNT-5505, is being presented at the American Society of Hematology Conference in December 2024 - what might good data at that point do to the share price!

What SNT SHOULD Be doing is drawing attention to the company's potential and the excellent investment opportunity presenting itself. All speculative bio is a risk - but this one certainly has favourable odds.